ES2682670T3 - Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas - Google Patents

Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas Download PDF

Info

Publication number
ES2682670T3
ES2682670T3 ES12773653.6T ES12773653T ES2682670T3 ES 2682670 T3 ES2682670 T3 ES 2682670T3 ES 12773653 T ES12773653 T ES 12773653T ES 2682670 T3 ES2682670 T3 ES 2682670T3
Authority
ES
Spain
Prior art keywords
positive bacteria
detection
treatment
gram positive
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12773653.6T
Other languages
English (en)
Spanish (es)
Inventor
Vincent A. Fischetti
Jonathan SCHMITZ
Daniel GILMER
Chad Euler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2682670T3 publication Critical patent/ES2682670T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES12773653.6T 2011-04-21 2012-04-20 Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas Active ES2682670T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477836P 2011-04-21 2011-04-21
US201161477836P 2011-04-21
PCT/US2012/034456 WO2012145630A2 (en) 2011-04-21 2012-04-20 Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria

Publications (1)

Publication Number Publication Date
ES2682670T3 true ES2682670T3 (es) 2018-09-21

Family

ID=47042182

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12773653.6T Active ES2682670T3 (es) 2011-04-21 2012-04-20 Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas

Country Status (12)

Country Link
US (7) US9034322B2 (enExample)
EP (2) EP3252155A1 (enExample)
JP (4) JP6139509B2 (enExample)
CN (4) CN103857410A (enExample)
AU (3) AU2012245357B2 (enExample)
CA (1) CA2833409A1 (enExample)
DK (1) DK2699253T3 (enExample)
ES (1) ES2682670T3 (enExample)
HK (2) HK1244503A1 (enExample)
IL (4) IL228869B (enExample)
MX (4) MX383544B (enExample)
WO (1) WO2012145630A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
US20140179594A1 (en) * 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
NL2007038C2 (en) * 2011-07-04 2013-01-07 Vereniging Voor Christelijk Hoger Onderwijs System and method for predicting the viability of a body tissue in a patient, and measuring device used therein.
JP6608697B2 (ja) 2012-05-09 2019-11-20 コントラフェクト コーポレイション グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
RU2646102C2 (ru) 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
EP3164146B1 (en) * 2014-06-26 2019-12-25 The Rockefeller University Acinetobacter lysins
CN104726439B (zh) * 2015-04-13 2017-11-14 武汉菲吉乐科生物科技有限公司 一种广谱的链球菌裂解酶及其应用
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
EP3328417A4 (en) * 2015-07-31 2019-02-06 The Regents of The University of California MYCOBACTERIUM LYSTERASE: A NEW TREATMENT FOR AKNE
EP3341013A4 (en) * 2015-09-13 2018-07-18 The Rockefeller University Clostridium difficile BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF Clostridium difficile BACTERIA INFECTION
EP3349781A2 (en) 2015-09-17 2018-07-25 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
DK3454888T3 (da) 2016-05-12 2021-04-26 Contrafect Corp Bouillon-mikrofortyndingsfremgangsmåde til evaluering og bestemmelse af minimal inhibitorisk koncentration for antibakterielle polypeptider
US20220023399A1 (en) * 2017-07-10 2022-01-27 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
CA3085644A1 (en) 2017-12-12 2019-06-20 Contrafect Corporation Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
CN111788299A (zh) * 2018-01-05 2020-10-16 阿兹特拉公司 葡萄球菌属细菌的营养缺陷型菌株
MX2020008860A (es) * 2018-02-26 2020-12-10 Contrafect Corp Lisinas plyss2 modificadas y sus usos.
KR102073094B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-3 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073088B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-2 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
KR102073086B1 (ko) * 2018-06-04 2020-02-04 (주)인트론바이오테크놀로지 신규한 스트렙토코커스 수이스 박테리오파지 Str-SUP-1 및 이의 스트렙토코커스 수이스 균 증식 억제 용도
EP3837348A4 (en) * 2018-08-17 2022-07-27 Becton, Dickinson and Company TESTING FOR ANTIBIOTIC SENSITIVITY USING MICRODROPLET
WO2020077286A1 (en) 2018-10-12 2020-04-16 Quidel Corporation Extraction reagent for use in an assay for detection of group a streptococcus
CA3134154A1 (en) * 2019-03-22 2020-10-01 Contrafect Corporation Method of treating infective endocarditis
MX2021012166A (es) * 2019-04-05 2021-11-03 Contrafect Corp Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
JP2022526624A (ja) * 2019-04-11 2022-05-25 コントラフェクト コーポレイション 骨及び関節の感染を治療及び予防する方法
IL297953A (en) * 2020-05-19 2023-01-01 Contrafect Corp Modified plyss2 lysines and antibiotic combinations for use against gram-positive bacteria
US20220087266A1 (en) * 2020-09-22 2022-03-24 Mars, Incorporated Compositions and methods for controlling mycotoxin production
CN114480299B (zh) * 2020-10-27 2023-08-29 暨南大学 一种蜡样芽胞杆菌噬菌体及其应用
CA3203004A1 (en) * 2020-11-25 2022-06-02 Laboratory Corporation Of America Holdings Methods and systems for the detection of microorganisms using infectious agents
CN112760312B (zh) * 2021-01-20 2022-06-17 华中农业大学 一种裂解革兰氏阳性菌的裂解酶plyssX609及其应用
WO2023049747A1 (en) * 2021-09-22 2023-03-30 Elanco Us Inc. Streptococcus suis lytic enzyme compositions and methods of use thereof
KR102742550B1 (ko) * 2022-07-26 2024-12-18 주식회사 인트론바이오테크놀로지 연쇄상구균에 대하여 용균 활성을 갖는 항균단백질
WO2024059184A1 (en) * 2022-09-16 2024-03-21 The Johns Hopkins University Machine learning systems and related aspects for the detection of disease states
CN116640754B (zh) * 2023-07-21 2023-10-10 临沂大学 一种链球菌前噬菌体裂解酶lys224及应用
CN117965624B (zh) * 2023-10-11 2024-12-17 圆因(北京)生物科技有限公司 一种用于编码耐甲氧西林金黄色葡萄球菌内溶素的线性dna、线性rna及其质粒表达载体
CN118272361A (zh) * 2024-05-13 2024-07-02 内蒙古农业大学 一种发酵粘液乳杆菌噬菌体裂解酶LysLFP01及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278378A (en) 1962-04-19 1966-10-11 Schindler Charles Alvin Staphylococcus-derived antibiotic
US3398056A (en) 1964-07-10 1968-08-20 Mead Johnson & Co Process for producing lysostaphin by fermentation
US3594284A (en) 1968-06-04 1971-07-20 Mead Johnson & Co Lysostaphin fermentation with accelerated time cycle
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
WO1986005803A1 (fr) 1985-03-30 1986-10-09 Marc Ballivet Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
AU8108587A (en) 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
US4948580A (en) 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
JPH02258718A (ja) 1989-03-31 1990-10-19 Nippon Kayaku Co Ltd ペースト状基剤及び製剤
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US20060292135A1 (en) * 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
HK1047243A1 (zh) 1999-02-25 2003-02-14 新眼界诊断公司 預防性和治療性治療鏈球菌感染的方法
CN1352567A (zh) * 1999-02-25 2002-06-05 新眼界诊断公司 预防性和治疗性治疗链球菌感染的方法
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
AU2003291614A1 (en) 2002-05-17 2004-04-08 New Horizons Diagnostics Corporation Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
US8326388B2 (en) 2002-10-31 2012-12-04 Toshiba Medical Systems Corporation Method and apparatus for non-invasive measurement of living body characteristics by photoacoustics
US7217791B2 (en) * 2002-11-07 2007-05-15 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
US7582729B2 (en) * 2003-05-15 2009-09-01 The Rockefeller University Nucleic acids and polypeptides of C1 bacteriophage and uses thereof
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
EP1744779A2 (en) 2004-03-24 2007-01-24 The Rockfeller University Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP2360248A1 (en) 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
IE20060488A1 (en) * 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent
DE102006061002A1 (de) * 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
CA2706600A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
CA2729160C (en) 2008-07-03 2017-11-14 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
US8481289B2 (en) * 2008-07-24 2013-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Triple acting antimicrobials that are refractory to resistance development
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
KR101016918B1 (ko) * 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
CN103080307A (zh) * 2010-01-25 2013-05-01 美艾利尔斯卡保罗有限公司 A25噬菌体溶解酶
US20140179594A1 (en) * 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock

Also Published As

Publication number Publication date
JP6284976B2 (ja) 2018-02-28
US20140072549A1 (en) 2014-03-13
IL287530A (en) 2021-12-01
IL271300A (en) 2020-01-30
AU2017202728A1 (en) 2017-05-18
AU2017202728B2 (en) 2019-04-04
US20150267185A1 (en) 2015-09-24
MX2013012241A (es) 2014-05-07
JP6735796B2 (ja) 2020-08-05
WO2012145630A2 (en) 2012-10-26
MX2021007008A (es) 2022-06-02
US20220064615A1 (en) 2022-03-03
CN108578685A (zh) 2018-09-28
NZ713076A (en) 2017-05-26
CA2833409A1 (en) 2012-10-26
CN103857410A (zh) 2014-06-11
US11111484B2 (en) 2021-09-07
JP6139509B2 (ja) 2017-05-31
JP2019022504A (ja) 2019-02-14
IL271300B (en) 2021-12-01
DK2699253T3 (en) 2018-07-16
IL228869A0 (en) 2013-12-31
JP2014518849A (ja) 2014-08-07
CN107189997A (zh) 2017-09-22
US20200002694A1 (en) 2020-01-02
JP2016147903A (ja) 2016-08-18
CN115887627A (zh) 2023-04-04
US20220127590A1 (en) 2022-04-28
JP6587655B2 (ja) 2019-10-09
MX336427B (es) 2016-01-18
NZ731111A (en) 2019-06-28
JP2017171686A (ja) 2017-09-28
EP2699253A2 (en) 2014-02-26
IL266476A (en) 2019-06-30
HK1247956A1 (en) 2018-10-05
NZ616945A (en) 2015-11-27
US20230167427A9 (en) 2023-06-01
AU2012245357B2 (en) 2017-06-08
IL228869B (en) 2019-05-30
US10544407B2 (en) 2020-01-28
MX370442B (es) 2019-12-13
EP2699253A4 (en) 2015-07-01
EP2699253B1 (en) 2018-03-28
MX383544B (es) 2025-03-14
AU2019204660A1 (en) 2019-07-18
US11155799B2 (en) 2021-10-26
WO2012145630A3 (en) 2014-05-01
US9034322B2 (en) 2015-05-19
US9914915B2 (en) 2018-03-13
AU2019204660B2 (en) 2021-01-28
AU2012245357A1 (en) 2013-11-14
US20170298334A1 (en) 2017-10-19
US20200149025A1 (en) 2020-05-14
IL266476B (en) 2020-01-30
HK1244503A1 (zh) 2018-08-10
EP3252155A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
ES2682670T3 (es) Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
WO2018013583A3 (en) Medicinal vaginal lactobacillus cocktail
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
GB201016733D0 (en) Compounds and their use
MX347600B (es) Uso de una composicion que comprende un peptido antimicrobiano como un conservador de alimentos.
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
RU2018121290A (ru) Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
JP2017532343A5 (enExample)
MX384834B (es) Novedoso bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga y su uso para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
WO2010123200A3 (ko) 병원성 장내세균을 사멸시키는 박테리오파지
AR073810A1 (es) Polipeptidos que tienen actividad antimicrobiana
WO2018155813A3 (ko) 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
ES2955834T3 (es) Variantes de plantaricina nc8alphabeta
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
CU24746B1 (es) Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
NZ700467A (en) Treatments suitable for malassezia infections
MY199203A (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
PH12013500692A1 (en) Antimicrobial protein